Valuation: Alector, Inc.

Market Cap 179M 156M 144M 133M 253M 17.05B 257M 1.72B 677M 8.4B 671M 657M 28.87B P/E 2026 *
-1.88x
P/E 2027 * -2.51x
Enterprise Value -68.38M -59.81M -55.17M -50.96M -96.69M -6.52B -98.31M -659M -259M -3.21B -257M -251M -11.05B EV / Sales 2026 *
-9.97x
EV / Sales 2027 * -6.45x
Free-Float
86.83%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-1.53%
1 week-21.84%
Current month-19.90%
1 month+5.92%
3 months-34.29%
6 months-13.44%
Current year+3.21%
1 week 1.48
Extreme 1.475
2.06
1 month 1.41
Extreme 1.41
2.14
Current year 1.41
Extreme 1.41
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
39.22
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 2013-04-30
Director of Finance/CFO 52 2025-06-19
Chief Tech/Sci/R&D Officer - 2016-12-31
Director TitleAgeSince
Director/Board Member 71 2013-04-30
Director/Board Member 72 2018-09-30
Chairman 77 2023-06-12
Date Insider Type Main position Quantity % Market Cap.
Jul. 08Free

Controller/Auditor

20,000 0.0180%
Jun. 16Free

Director

38,150 0.0344%
Jun. 16Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
-1.53%-21.84%-6.40%-74.84% 179M
-4.14%-8.06%+57.35%+117.24% 54.63B
+1.84%-0.66%+75.79%+93.87% 54.88B
-2.24%+3.59%+19.60%+466.72% 25.06B
-1.60%-6.21%-19.69%-14.84% 23.14B
+2.43%+1.06%+47.70%-0.11% 19.88B
-3.19%0.00%+33.99%-26.87% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
-1.05%+1.16%+25.08%+196.28% 14.2B
+8.74%+3.51%+53.81% - 15.36B
Average -0.76%-2.43%+48.24%+123.85% 24.14B
Weighted average by Cap. -0.91%-1.47%+55.00%+137.62%

Financials

2026 *2027 *
Net sales 6.86M 6M 5.53M 5.11M 9.7M 654M 9.86M 66.1M 25.96M 322M 25.75M 25.19M 1.11B 22.88M 20.01M 18.46M 17.05M 32.35M 2.18B 32.9M 221M 86.62M 1.08B 85.91M 84.04M 3.7B
Net income -94.11M -82.32M -75.93M -70.13M -133M -8.98B -135M -907M -356M -4.42B -353M -346M -15.2B -96.62M -84.51M -77.95M -71.99M -137M -9.21B -139M -931M -366M -4.54B -363M -355M -15.61B
Net Debt -247M -216M -199M -184M -349M -23.57B -355M -2.38B -936M -11.61B -928M -908M -39.92B -326M -285M -263M -243M -461M -31.13B -469M -3.15B -1.24B -15.33B -1.23B -1.2B -52.72B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
26-07-10 $1.610 -1.53% 597,218
26-07-09 $1.635 -10.66% 589,285
26-07-08 $1.830 -5.18% 643,891
26-07-07 $1.930 -0.52% 416,164
26-07-06 $1.940 -5.83% 588,496
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.610USD
Average target price
3.100USD
Spread / Average Target
+92.55%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock